Erratum to “Effects of Probiotic Supplementation on Short Chain Fatty Acids in the App\textsuperscript{NL-G-F} Mouse Model of Alzheimer’s Disease”

Pre-press 8 March 2022

Harpreet Kaur, Svetlana Golovko, Mikhail Y. Golovko, Surjeet Singh, Diane C. Darland and Colin K. Combs


https://content.iospress.com/articles/journal-of-neuromuscular-diseases/jad200436

It has been brought to the authors’ attention that the formulation of VSL\textsuperscript{#3}® may have changed subsequent to its use in the article as published in final form in 2020. For the sake of clarity, the product commercially distributed as VSL\textsuperscript{#3}® circa 2016, and as procured by the authors and referred to herein as “VSL\textsuperscript{#3},” comprised eight strains of lactic acid producing bacteria: \textit{Lactobacillus plantarum}, \textit{Lactobacillus delbrueckii subspecies Bulgaricus}, \textit{Lactobacillus paracasei}, \textit{Lactobacillus acidophilus}, \textit{Bifidobacterium breve}, \textit{Bifidobacterium longum}, \textit{Bifidobacterium infantis}, and \textit{Streptococcus salivarius subspecies thermophilus}. This same formulation is understood to now be commercially available as Visbiome\textsuperscript{®}.

The authors are not in any way affiliated with the owners of either trademark, nor do the authors take any position with respect to the business or legal relationship between such parties, or on any assertion, contention, or claim between such parties.